{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:55:04Z","timestamp":1785434104994,"version":"3.56.0"},"reference-count":16,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can. J. Neurol. Sci."],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec id=\"S0317167126105629_as1\">\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Foslevodopa-foscarbidopa (LDp\/CDp) is a soluble formulation of levodopa\/carbidopa delivered as a continuous subcutaneous infusion for the treatment of motor fluctuations in people with Parkinson\u2019s disease. No real-world use data exist regarding its efficacy and safety from a high-volume Canadian center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0317167126105629_as2\">\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This is an ambispective longitudinal study (with the second visit at 1 month of enrollment) in patients with advanced Parkinson\u2019s disease from a tertiary care movement disorder center in Canada.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0317167126105629_as3\">\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>The primary objective of the study was to examine the efficacy of LDp\/CDp in improving MDS UPDRS III scores, EURO-Q Index, EURO Q VAS score and ON time while reducing OFF time. Secondary objectives focused on safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0317167126105629_as4\">\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The study was conducted from April 2024 to August 2025, with the prospective part comprising 11 patients and the retrospective part 53 patients. There was a significant (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.05) improvement in clinical efficacy parameters like the MDS UPDRS III (\u221211.37), OFF hours (\u22122.77), ON time without dyskinesias (+2.07), ON time with troublesome dyskinesias (\u22120.74 hours) and quality of life-related parameters like EURO Q Index (+0.10) and PDQ-39 (\u221210.78). One-fourth (26.5%) of the patients discontinued treatment, mostly due to infusion-site reactions or infections.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0317167126105629_as5\">\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>LDp\/CDp can be an effective treatment option for carefully selected patients with advanced Parkinson\u2019s disease and disabling motor complications. Appropriate hygiene measures may reduce the proportion of infusion site reactions, thereby improving patient retention on LDp\/CDp infusion.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1017\/cjn.2026.10562","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T06:30:57Z","timestamp":1770705057000},"page":"1-7","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Side-Effect Profile of Foslevodopa-Foscarbidopa Subcutaneous Infusion in Patients with Advanced Parkinson\u2019s Disease: An Ambispective Longitudinal Study"],"prefix":"10.1017","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0507-1866","authenticated-orcid":false,"given":"Animesh","family":"Das","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02dwcqs71","id-type":"ROR","asserted-by":"publisher"}],"name":"All India Institute of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo Trocha","family":"Ramos","sequence":"additional","affiliation":[{"name":"University of Western Ontario Schulich School of Medicine & Dentistry"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Russell","sequence":"additional","affiliation":[{"name":"University of Western Ontario Schulich School of Medicine & Dentistry"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7513-8651","authenticated-orcid":false,"given":"Mandar","family":"Jog","sequence":"additional","affiliation":[{"name":"University of Western Ontario"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"S0317167126105629_ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00533-1"},{"key":"S0317167126105629_ref4","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27372"},{"key":"S0317167126105629_ref14","doi-asserted-by":"publisher","DOI":"10.1002\/mds.30069"},{"key":"S0317167126105629_ref15","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-191605"},{"key":"S0317167126105629_ref1","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-181474"},{"key":"S0317167126105629_ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00218-X"},{"key":"S0317167126105629_ref12","first-page":"S23","article-title":"Open-label extension study of long-term safety and tolerability of foslevodopa\/foscarbidopa for treatment of advanced Parkinson\u2019s disease [abstract]","volume":"38","author":"Fung","year":"2023","journal-title":"Mov Disord"},{"key":"S0317167126105629_ref11","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.70245"},{"key":"S0317167126105629_ref6","first-page":"100239","article-title":"Continuous subcutaneous foslevodopa\/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson\u2019s disease: considerations for initiation and maintenance","volume":"10","author":"Fung","year":"2024","journal-title":"Clin Park Relat Disord"},{"key":"S0317167126105629_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(06)70521-X"},{"key":"S0317167126105629_ref10","first-page":"e5","article-title":"Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced parkinson\u2019s disease: a randomised, double-blind, active-controlled, phase 3 trial","volume":"22","author":"Soileau","year":"2023","journal-title":"Erratum in: Lancet Neurol"},{"key":"S0317167126105629_ref2","unstructured":"2. Parkinson Canada. Ontario roundtable report. Accessed January 4, 2026, 2022. https:\/\/www.parkinson.ca\/wp-content\/uploads\/PS-Ontario-FinalReport-May2022-V03.pdf."},{"key":"S0317167126105629_ref7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000205963"},{"key":"S0317167126105629_ref5","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29066"},{"key":"S0317167126105629_ref13","doi-asserted-by":"publisher","DOI":"10.1002\/mds.30121"},{"key":"S0317167126105629_ref16","doi-asserted-by":"publisher","DOI":"10.1111\/ner.13360"}],"container-title":["Canadian Journal of Neurological Sciences \/ Journal Canadien des Sciences Neurologiques"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0317167126105629","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T06:58:33Z","timestamp":1784271513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0317167126105629\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":16,"alternative-id":["S0317167126105629"],"URL":"https:\/\/doi.org\/10.1017\/cjn.2026.10562","relation":{},"ISSN":["0317-1671","2057-0155"],"issn-type":[{"value":"0317-1671","type":"print"},{"value":"2057-0155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]}}}